Photo taken from ESMO/LinkedIn
May 24, 2024, 01:43
ESMO – In an interim analysis presented at ESMOBreast24 of atezolizumab and sacituzumab in locally advanced or metastatic triple-negative breast cancer
ESMO shared a post on LinkedIn:
“In an interim analysis presented at ESMOBreast24, first-line treatment with the combination of the PD-L1 inhibitor atezolizumab and sacituzumab govitecan showed a higher objective response rate compared to control in patients with previously untreated PD-L1 positive locally advanced or metastatic triple-negative breast cancer.”
Read further.
Source: ESMO/LinkedIn